Literature DB >> 16170332

The benefit of influenza vaccination after bone marrow transplantation.

C M Machado1, M R A Cardoso, I F da Rocha, L S V Boas, F L Dulley, C S Pannuti.   

Abstract

Influenza vaccine is recommended yearly for recipients after the sixth month of BMT. Although a higher risk of complications of influenza is expected to occur in BMT patients, no study has addressed the clinical efficacy of influenza vaccination in this setting. Focusing on the clinical benefits of influenza vaccination, we evaluated the risk factors for influenza infection in a cohort of 177 BMT recipients followed up for 1 year. Influenza was diagnosed in 39 patients. Multivariate analyses showed that seasonal exposure and more aggressive conditioning regimens were independently associated with increased risk for influenza. Influenza vaccination and steroid use showed a protective role. Of the 43 patients who had received BMT longer than 6 months, 19 were vaccinated (compliance rate = 44.2%) and vaccine efficacy was 80%. We conclude that influenza vaccination plays an important role in protecting BMT recipients against influenza and all efforts should be made to ensure good compliance with vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170332     DOI: 10.1038/sj.bmt.1705159

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  29 in total

1.  CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults.

Authors:  Aprille Seidel; David Smith; Edward Yung; Lia Aquino; Tumul Srivastava; Vinod Pullarkat; Ricardo Spielberger; Stephen J Forman; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-08       Impact factor: 5.742

2.  Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Bilal Mohty; Michael Bel; Marija Vukicevic; Monika Nagy; Emmanuel Levrat; Sara Meier; Stephane Grillet; Christophe Combescure; Laurent Kaiser; Yves Chalandon; Jakob Passweg; Claire-Anne Siegrist; Eddy Roosnek
Journal:  Haematologica       Date:  2011-03-21       Impact factor: 9.941

Review 3.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

4.  Low-Cost Intervention to Increase Influenza Vaccination Rate at a Comprehensive Cancer Center.

Authors:  Petros D Grivas; Sumana Devata; Rami Khoriaty; Philip S Boonstra; Joshua Ruch; Kevin McDonnell; Leonel Hernandez-Aya; Joshua Wilfong; Jeffrey Smerage; Michael G Ison; Joseph N S Eisenberg; Maria Silveira; Kathleen A Cooney; Francis P Worden
Journal:  J Cancer Educ       Date:  2017-12       Impact factor: 2.037

5.  A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.

Authors:  Y Natori; A Humar; J Lipton; D D Kim; P Ashton; K Hoschler; D Kumar
Journal:  Bone Marrow Transplant       Date:  2017-03-06       Impact factor: 5.483

Review 6.  Influenza prevention and treatment in transplant recipients and immunocompromised hosts.

Authors:  Michael G Ison
Journal:  Influenza Other Respir Viruses       Date:  2013-11       Impact factor: 4.380

Review 7.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

8.  Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Yusuke Fukatsu; Yasuyuki Nagata; Miwa Adachi; Tomohiro Yagyu; Takaaki Ono
Journal:  Int J Hematol       Date:  2016-12-10       Impact factor: 2.490

Review 9.  Graft-versus-host disease.

Authors:  James L M Ferrara; John E Levine; Pavan Reddy; Ernst Holler
Journal:  Lancet       Date:  2009-03-11       Impact factor: 79.321

Review 10.  The challenge of respiratory virus infections in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh
Journal:  Br J Haematol       Date:  2008-09-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.